An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures;
Aged 18 to 79 years;
Histologically confirmed pancreatic ductal adenocarcinoma;
Macroscopic complete tumor removal (R0 or R1 resection);
Prior neoadjuvant therapy for pancreatic cancer;
Subjects with borderline resectable pancreatic cancer;
Present or past history of metastatic or locally recurrent pancreatic cancer;
Evidence of malignant ascites;
CARsgen Therapeutics Co., Ltd.
Lead sponsor
Fudan University
Collaborator